Therefore, numerous researchers considered isocitrate dehydrogenase as an actionable target and have been performed over the past decade to take advantage of the inhibition of mutant IDH enzymes through pharmacological inhibitors or small molecules to disrupt tumor metabolism and alter thereby tumor growth. The gene discussed is IDH1; the disease is neoplasm.